These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34846697)

  • 1. Chiglitazar: First Approval.
    Deeks ED
    Drugs; 2022 Jan; 82(1):87-92. PubMed ID: 34846697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator-Activated Receptor Pan-Agonist, in Patients < 65 and ≥ 65 Years With Type 2 Diabetes.
    Li X; Yu J; Wu M; Li Q; Liu J; Zhang H; Zhu X; Li C; Zhang J; Ning Z; Ding Y
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):789-796. PubMed ID: 33345463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study.
    Xu HR; Zhang JW; Chen WL; Ning ZQ; Li XN
    Clin Drug Investig; 2019 Jun; 39(6):553-563. PubMed ID: 31037611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma proteome profiling reveals the therapeutic effects of the PPAR pan-agonist chiglitazar on insulin sensitivity, lipid metabolism, and inflammation in type 2 diabetes.
    Wang X; Wang Y; Hou J; Liu H; Zeng R; Li X; Han M; Li Q; Ji L; Pan D; Jia W; Zhong W; Xu T
    Sci Rep; 2024 Jan; 14(1):638. PubMed ID: 38182717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of chiglitazar on glycemic control in type 2 diabetic patients with metabolic syndrome and insulin resistance: A pooled data analysis from two phase III trials.
    Ning Z; Ai G; Chen B; Yao H; Cao H; Pan D; Lu X
    J Diabetes; 2024 Feb; 16(2):e13484. PubMed ID: 37853916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP).
    Ji L; Song W; Fang H; Li W; Geng J; Wang Y; Guo L; Cai H; Yang T; Li H; Yang G; Li Q; Liu K; Li S; Liu Y; Shi F; Li X; Gao X; Tian H; Ji Q; Su Q; Zhou Z; Wang W; Zhou Z; Li X; Xu Y; Ning Z; Cao H; Pan D; Yao H; Lu X; Jia W
    Sci Bull (Beijing); 2021 Aug; 66(15):1571-1580. PubMed ID: 36654286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imeglimin Hydrochloride: First Approval.
    Lamb YN
    Drugs; 2021 Sep; 81(14):1683-1690. PubMed ID: 34472031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
    Li PP; Shan S; Chen YT; Ning ZQ; Sun SJ; Liu Q; Lu XP; Xie MZ; Shen ZF
    Br J Pharmacol; 2006 Jul; 148(5):610-8. PubMed ID: 16751799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bexagliflozin: First Approval.
    Hoy SM
    Drugs; 2023 Apr; 83(5):447-453. PubMed ID: 36867399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
    Patsouris D; Müller M; Kersten S
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MK-767. Kyorin/Banyu/Merck.
    Calkin AC; Thomas MC; Cooper ME
    Curr Opin Investig Drugs; 2003 Apr; 4(4):444-8. PubMed ID: 12808885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trelagliptin: First Global Approval.
    McKeage K
    Drugs; 2015 Jul; 75(10):1161-4. PubMed ID: 26115728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albiglutide: first global approval.
    Poole RM; Nowlan ML
    Drugs; 2014 Jun; 74(8):929-38. PubMed ID: 24861909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ertugliflozin: First Global Approval.
    Markham A
    Drugs; 2018 Mar; 78(4):513-519. PubMed ID: 29476348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.
    Cox SL
    Drugs Today (Barc); 2005 Sep; 41(9):579-87. PubMed ID: 16341289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis.
    Lin C; Li ZL; Cai XL; Hu SY; Lv F; Yang WJ; Ji LN
    World J Diabetes; 2023 Oct; 14(10):1573-1584. PubMed ID: 37970134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semaglutide: First Global Approval.
    Dhillon S
    Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The next generation of PPAR drugs: do we have the tools to find them?
    Shearer BG; Billin AN
    Biochim Biophys Acta; 2007 Aug; 1771(8):1082-93. PubMed ID: 17602866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.